Prostate Cancer: Diffusion-Weighted Imaging Versus Dynamic-Contrast Enhanced Imaging for Tumor Localization—A Meta-Analysis
暂无分享,去创建一个
[1] P. Mozer,et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. , 2012, European urology.
[2] Cher Heng Tan,et al. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. , 2012, AJR. American journal of roentgenology.
[3] Jiani Hu,et al. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. , 2012, AJR. American journal of roentgenology.
[4] Baris Turkbey,et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. , 2012, AJR. American journal of roentgenology.
[5] Jian-Rong Xu,et al. Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. , 2012, Academic radiology.
[6] J. Fütterer,et al. ESUR prostate MR guidelines 2012 , 2012, European Radiology.
[7] M. Colombel,et al. Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? , 2012, European Radiology.
[8] Baris Turkbey,et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. , 2011, The Journal of urology.
[9] Thomas Hambrock,et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. , 2011, Radiology.
[10] T. Sone,et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. , 2011, AJR. American journal of roentgenology.
[11] Ralph Strecker,et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. , 2011, Radiology.
[12] Yousef Mazaheri,et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. , 2011, Radiology.
[13] Josep Comet,et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. , 2011, AJR. American journal of roentgenology.
[14] Dan Stoianovici,et al. Advancements in MR imaging of the prostate: from diagnosis to interventions. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[15] Thomas Hambrock,et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. , 2011, Radiology.
[16] François Cornud,et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging , 2011, BJU international.
[17] B. Carey,et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.
[18] S. Verma,et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.
[19] Aytekin Oto,et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. , 2010, Radiology.
[20] D. Portalez,et al. Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies , 2010, European Radiology.
[21] C. Kim,et al. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. , 2010, AJR. American journal of roentgenology.
[22] Kazuro Sugimura,et al. Prostate cancer detection with 3 T MRI: Comparison of diffusion‐weighted imaging and dynamic contrast‐enhanced MRI in combination with T2‐weighted imaging , 2010, Journal of magnetic resonance imaging : JMRI.
[23] Baris Turkbey,et al. Imaging localized prostate cancer: current approaches and new developments. , 2009, AJR. American journal of roentgenology.
[24] Masao Fukunaga,et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. , 2008, Radiology.
[25] Matthias Taupitz,et al. Evaluation of Normal Prostate Tissue, Chronic Prostatitis, and Prostate Cancer by Quantitative Perfusion Analysis Using a Dynamic Contrast-Enhanced Inversion-Prepared Dual-Contrast Gradient Echo Sequence , 2008, Investigative radiology.
[26] Oliver Sartor,et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. , 2007, The Journal of urology.
[27] Javier Zamora,et al. Meta-DiSc : a software for meta-analysis of test accuracy data , 2015 .
[28] Wolfhard Semmler,et al. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI , 2004, European Radiology.
[29] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[30] D P Dearnaley,et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. , 2000, Clinical radiology.
[31] Mariann F. Brown,et al. Microvascularity in benign prostatic hyperplasia , 1995, The Prostate.
[32] L E Moses,et al. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. , 1993, Statistics in medicine.